Regeneron price target raised to $367 from $315 at Brean Capital Brean Capital raised Buy rated Regeneron's price target to $367 based on positive results from the VIVID/VISTA trials with Eylea for DME. The firm expects Eylea peak sales for DME to exceed peak sales for wet AMD.
News For REGN From The Last 14 Days
Check below for free stories on REGN the last two weeks.
Vertex, Regeneron speculated to be merger targets, TheStreet says Among the predictions for the biotech sector in 2014 made by David Sobek of TheStreet.com was a call for "at least two" mergers between large-cap companies. Sobek predict Sanofi (SNY) will buy Regeneron (REGN) and that Bristol-Myers Squibb (BMY) will acquire Vertex Pharmaceuticals (VRTX). Reference Link